Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jonathan Rodrigues

Allergy & Immunology Bismarck, ND Medical Doctor

NPI 1326351131 CMS profile 196745

715 E Broadway Ave, Bismarck, ND 58501

Open in the dashboard

General payments

$54,190

116 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jonathan Rodrigues of Bismarck, ND is reported in the CMS Open Payments database as having received $54,190 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $202 9
2021 General $262 17
2020 General $2,364 14
2019 General $51,362 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Rodrigues
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jonathan Rodrigues were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jonathan Rodrigues Allergy & Immunology median Middle half National median
2019 $51,362 $594 $163–$1,512 $163
2020 $2,364 $426 $106–$1,233 $114
2021 $262 $638 $157–$1,708 $132
2022 $202 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $47,090 57 payments
  2. CSL Behring $6,343 15 payments
  3. GlaxoSmithKline, LLC. $214 11 payments
  4. Genzyme Corporation $189 11 payments
  5. Horizon Therapeutics plc $45 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $44 3 payments
  7. Regeneron Healthcare Solutions, Inc. $42 2 payments
  8. Novartis Pharmaceuticals Corporation $34 1 payment
  9. Octapharma USA, Inc. $31 2 payments
  10. Pfizer Inc. $28 2 payments
  11. Other $130 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,225 17 payments
  2. Travel and Lodging $6,812 17 payments
  3. Honoraria $4,290 1 payment
  4. Food and Beverage $2,836 79 payments
  5. Education $27 2 payments
Products named General payments · program years 2019–2022
  1. FASENRA $46,816 49 payments
  2. Haegarda $6,325 14 payments
  3. DUPIXENT Immunology $188 10 payments
  4. NUCALA Respiratory $139 6 payments
  5. DUPIXENT Immunology $95 6 payments
  6. TEZSPIRE $62 1 payment
  7. NUCALA Immunology $51 4 payments
  8. ACTIMMUNE $45 3 payments
  9. DUPIXENT Inflammation And Immunology $42 2 payments
  10. COSENTYX $34 1 payment
  11. Other $314 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record